Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Fortress Biotech ( (FBIO) ) has provided an announcement.
On November 14, 2025, Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, resubmitted the NDA for CUTX-101 to the FDA, a treatment for Menkes disease in pediatric patients. Cyprium retains ownership of any Priority Review Voucher from the NDA approval and stands to gain royalties and up to $129 million in development and sales milestones.
The most recent analyst rating on (FBIO) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Fortress Biotech stock, see the FBIO Stock Forecast page.
Spark’s Take on FBIO Stock
According to Spark, TipRanks’ AI Analyst, FBIO is a Neutral.
The overall stock score is primarily impacted by the company’s financial instability, characterized by declining revenues and high leverage. While the earnings call provided some positive insights regarding new product performance and future growth potential, the technical analysis and valuation metrics remain weak, contributing to a lower overall score.
To see Spark’s full report on FBIO stock, click here.
More about Fortress Biotech
Fortress Biotech, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of novel pharmaceutical products. Its subsidiary, Cyprium Therapeutics, Inc., is involved in creating treatments for rare diseases, with a market focus on pediatric conditions.
Average Trading Volume: 1,028,438
Technical Sentiment Signal: Hold
Current Market Cap: $77.96M
See more insights into FBIO stock on TipRanks’ Stock Analysis page.